Entrepreneurs Investment Meet
Pharmaceutical companies are actively developing analogues of existing antibiotic classes based on innovative approaches to fight bacterial infections. Key players operating in the global antibiotic market include Pfizer Inc., Astellas Pharma, Inc, Roche, Novartis AG, Bristol-Myers Squibb Co., Bayer HealthCare AG, Abbott Laboratories, MiddleBrook Pharmaceuticals, Takeda Pharmaceutical Company, Ltd., Daiichi Sankyo Company, Ltd., GlaxoSmithKline Plc, Eli Lilly and Co., and Kyorin Pharmaceutical Co., Ltd. Supportive government legislations, such as the Generating Antibiotics Incentives Now (GAIN) Act are expected to expedite the approval process. GAIN Act has provisions which facilitate development of therapy against antibiotic resistant pathogens.
Related Conference of Entrepreneurs Investment Meet
21th International Conference on Allergic Diseases and Clinical Immunology
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
Entrepreneurs Investment Meet Conference Speakers
Recommended Sessions
- Antibiotics Alternative
- Antibiotic Prophylaxis
- Antibiotic Resistance
- Antibiotics
- Antibiotics and Public Health
- Antibiotics: Industrial Scope
- Antimicrobial
- Application of Antibiotics
- Current Challenge and Market
- Drug Discovery
- Entrepreneurs Investment Meet
- Immunology
- Interaction of Antibiotics
- Mechanism : Antibiotics
- Next Generation Approach
- Oncology Antibiotics
- Pediatric Antibiotics
- Types of Antibiotics
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)